Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Terns Pharmaceuticals develops small-molecule therapies for chronic diseases including cancer, metabolic disorders, and liver conditions.
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Biobeat is a med-tech company that develops remote patient monitoring and data collection tool.
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases.
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Mendra uses AI to accelerate clinical development and commercialization of breakthrough medicines for diseases with high unmet need.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
ProLynx is a biotechnology company that develops proprietary drug-delivery technologies to extend the half-life of therapeutic molecules.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
PierianDx is catalyzing global adoption of genomic sequencing in healthcare
Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies and autologous regenerative medicine.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
OrbiMed has invested in 289 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Medical. The firm invests across 19 different industry categories.
Among tracked funding rounds, Terns Pharmaceuticals received $650.0M in a Post-IPO Equity round. OrbiMed's total known invested capital is $23.6B.
OrbiMed's average investment size is $104.0M across its portfolio of 289 companies.
Recent OrbiMed portfolio additions include Amolyt Pharma, Keros Therapeutics, Terns Pharmaceuticals, 89bio, Emergence Therapeutics. These companies were founded in 2020 or later.